论文部分内容阅读
目的评价血浆组织纤溶酶原激活物抑制物-1(PAI-1)、D-二聚体(D-dimer,DD)检测在慢性阻塞性肺疾病(COPD)合并肺血栓栓塞症(PTE)诊断中的价值。方法分别对COPD合并PTE组和COPD组患者血浆PAI-1、DD含量进行比较,应用受试者工作曲线(ROC曲线)分析PAI-1、DD诊断COPD合并PTE时的敏感性、特异性、ROC曲线下面积同时计算其阳性率。结果COPD合并PTE组PAI-1、DD水平明显高于COPD组以98.5ng/L、1.85mg/L为阳性界点,PAI-1、DD两者联合诊断肺栓塞的敏感性为87.6%,特异性为85.6%,两者联合检测敏感、特异性明显高于PAI-1或DD单项(P<0.05)。结论PAI-1、DD及两者联合检测对于COPD合并PTE的有诊断价值,尤其是联合检测对COPD合并PTE的诊断具有重要意义。
Objective To evaluate the diagnostic value of plasma tissue plasminogen activator inhibitor-1 (PAI-1) and D-dimer (DD) in patients with chronic obstructive pulmonary disease (COPD) complicated with pulmonary thromboembolism (PTE) Diagnostic value. Methods The levels of plasma PAI-1 and DD in patients with COPD and PTE and COPD were compared. The sensitivity and specificity of PAI-1 and DD in diagnosing COPD with PTE were analyzed by receiver operating curve (ROC curve) Area under the curve at the same time calculate the positive rate. Results The PAI-1 and DD levels in patients with COPD and PTE were significantly higher than those in COPD patients (98.5ng / L and 1.85mg / L respectively). The sensitivity of PAI-1 and DD in diagnosing pulmonary embolism was 87.6% The sensitivity was 85.6%. The specificity and specificity of combined detection were significantly higher than those of PAI-1 or DD (P <0.05). Conclusions The combined detection of PAI-1, DD and both has diagnostic value for COPD combined with PTE, especially for the diagnosis of COPD combined with PTE.